Market Overview

Benzinga's Top Analyst Calls From April 6, 2018

Share:

These headlines first appeared on Benzinga Pro.

  • Cantor out defending NewLink Genetics Corp (NASDAQ: NLNK), says indoximod is differentiated vs epacadostat in response rates in more heavily pretreated patient population; thinks assuming failure of indoximod may be premature, but understands shares are likely pressured.
  • Buckingham Research maintains Buy rating and $15 target price on Gol Transportes Aéreos (NYSE: GOL), implying 20 percent upside. Says Gol's underlying fundamental outlook is “aided by a continued demand recovery in the context of a heavily restructured supply backdrop and commercial initiatives.”
  • KeyBanc upgrades Halyard Health, Inc. (NYSE: HYH) to Overweight, says upcoming events could raise growth expectations and restructuring and M&A efforts could drive accelerated EPS growth.
  • Mizuho out positive on Nektar Therapeutics (NASDAQ: NKTR), says Incyte’s (NASDAQ: INCY) epacadostat Phase 3 failure is a positive for the company, believes this news raises the possibility of a takeout by BMS in coming months.
  • Imperial Capital maintains Outperform rating on Halcón Resources Corp. (NYSE: HK), says co. is “ready to get active on its West Quito Draw position” following acquisition.

See Also:

Benzinga's Top Upgrades, Downgrades For April 6, 2018

5 Biggest Price Target Changes For Friday

 

Related Articles (GOL + HK)

View Comments and Join the Discussion!

Posted-In: Analyst Color Price Target Intraday Update Analyst Ratings

Latest Ratings

StockFirmActionPT
ZZZScotiaBankMaintains27.0
FSVScotiaBankMaintains128.0
FNScotiaBankMaintains38.0
CSUScotiaBankMaintains1,600.0
CXOScotiaBankDowngrades43.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com